

# Somerset Clinical Commissioning Group

Minutes of the **Somerset Prescribing Forum** held in **Meeting Room 2, Wynford House, Lufton Way, Yeovil, Somerset** on **Wednesday 18<sup>th</sup> January 2017**

<b>Present:</b>	Dr Geoff Sharp	GP Delegate (Central Mendip Commissioning Locality), Chair	GS
	Dr Clare Barlow	Chair, Drug & Therapeutics Committee, Taunton & Somerset NHS FT	CB
	Steve Du Bois	Chief Pharmacist- Head of Medicines Management, Somerset Partnership NHS Foundation Trust	SD
	Shaun Green	Associate Director, Head of Medicines Management, NHS Somerset CCG	SG
	Catherine Henley	Medicines Manager, NHS Somerset CCG	CH
	Gordon Jackson	Patient Representative	GJ
	Jean Perry	Commissioning Manager, NHS Somerset CCG	JP
	Jon Standing	Chief Pharmacist, Yeovil District Hospital	JS
	Zoe Talbot-White	Prescribing Support Technician, NHS Somerset CCG	ZT
<b>In attendance:</b>	Aadam Hasmi	Pharmacist, Shepton Mallet Treatment Centre	AH
<b>Apologies:</b>	Jon Beard	Chief Pharmacist, Taunton & Somerset NHS FT	JB
	Dr Orla Dunn	Consultant in Public Health, Somerset County Council	OD
	Ann Lee	Clinical Director, St Margaret's Hospice	AL
	Michael Lennox	Chief Officer, Somerset LPC	ML
	Dr Robert Munro	GP, Somerset Local Medical Committee representative	RM

- 1 WELCOME**  
GS welcomed everyone.
- 2 APOLOGIES**  
Apologies were provided as detailed above.
- 3 DECLARATIONS of INTEREST**  
No other changes were noted.
- 4 MINUTES OF THE MEETING HELD ON 9<sup>th</sup> November 2017**
  - 4.1** The Minutes of the meeting were agreed
  - 4.2** GS ran through the action points from the last meeting.  
The actions were on the agenda.
- 5 MATTERS ARISING (not otherwise on the agenda)**
  - 5.1 YDH Biosimilars Policy – Update**  
YDH have approved new policy and are happy to share with other organisations.-  
Complete
  - 5.2 RuH Biosimilars implementation– Update**  
RuH currently working on a new policy.  
YDH and TST policies will be shared. SG to update at next meeting.  
**Action SG**
  - 5.3 LMWH Bridging Guidance- YDH Update**  
This continues to be discussed internally at YDH. JS to update at next meeting.  
**Action JS**
  - 5.4 YDH & TST self-assessment against NICE QS120 Medicines optimisation**  
JS presented self-assessment and have action plan to internally raise gaps with  
internal governance. JB not present to update SPF at next meeting  
**Action JB**
  - 5.5 SomPar Medicines Management actions against CQC inspection report**  
No update. SD to update at next meeting.  
**Action SD**
  - 5.6 Aflibercept ‘Treat and Extend’ approach – update on progress with funding**  
Agreed to commission treat and extend.- Complete
  - 5.7 Updated Biological Treatment Algorithm for Rheumatoid Arthritis- for review**  
Discussed and approved.- Complete

**5.8 Autoprotect insulin pen needles- SomPar Risk assessment**

Risk assessment complete. Agreed that Mylife Clickfine autoprotect needles remain first line on formulary- Complete

**6 OTHER ISSUES**

**6.1 Standard Contract 17/18 to 18/19 technical guidance**

The new contract was noted

**6.2 Review of need for current range of Shared Care Guidelines  
Contractual discussion**

Shared care contract schedule was discussed. SPF recommended Somerset continues with current arrangements of presumed GP agreement to shared care of amber drugs. (Subject to LMC comments).

Trusts to be asked to update correspondence to set a timescale for rejection, if shared care not agreed. Eg 'I hope you will accept the shared care for drug X if you have any concerns or are not willing to accept shared care then please contact me within the next 14 days.'

**Action JS, JB & SD**

**6.3 Draft Shared Care Guidelines for ADHD and Acetylcholinesterase inhibitors and Memantine**

No guidelines were tabled. Bring to next meeting

**Action SD**

**6.4 Respiratory guidelines and Inhaler pathways**

Respiratory guidelines were discussed and approved.

**6.5 Model Hospital Data- Jon Beard and Jon Standing**

JS presented YDH model hospital data. This was noted. JB and JS will update SPF as this develops. - Complete

**6.6 YDH- Draft Hospital Transformation Plan - Jon Standing**

JS presented Transformational plan. This was noted. JB and JS will update SPF as this develops- Complete

**6.7 Inclusion of Yeovil Symphony Lead Pharmacist to the SPF membership-  
Discussion**

This was discussed and agreed- Complete

## 7 Formulary Applications

### 7.1 **Braltus<sup>®</sup> (tiotropium) 10mcg per delivered dose inhalation powder hard capsules Teva. For noting**

Approved- **GREEN**

### 7.2 **Sialanar<sup>®</sup> (glycopyrronium, bromide) 320mcg glycopyrronium/ml oral solution Proveca Limited**

(Licensed for symptomatic treatment of severe sialorrhoea in children and adolescents aged 3 years and older with chronic neurological disorders.

Colonis glycopyrronium bromide liquid contains 1mg/5ml glycopyrronium bromide. Cost £91 per 100ml – 10mg glycopyrronium bromide (50ml) costs £45.50

Sialanar glycopyrronium bromide liquid contains 400mcg/ml glycopyrronium bromide. At a price of £320 per 250ml – 10mg glycopyrronium bromide (25ml) costs £32.00

Shelf life = 2 years. Once opened it is 28 days)

Approved- **GREEN**. Colonis brand of glycopyrronium liquid to be removed now licensed product is available.

### 7.3 **Acidex<sup>®</sup> Advance**

(£2.21 for 250ml and £4.42 for 500ml)

Peppermint or Aniseed flavour

Each 10 ml contains:

Sodium Alginate 1000 mg

Potassium hydrogen carbonate 200 mg

the same as Gaviscon Advance: £2.56 for 250ml and £5.12 for 500ml)

Approved- **GREEN**

### 7.4 **Pipexus<sup>®</sup> - (prolonged release pramipexole tablets)**

(Bioequivalent to and 50% less expensive than originator brand Mirapexin<sup>®</sup>)

Approved- **GREEN**

### 7.5 **Ventra<sup>®</sup> (esomeprazole gastro-resistant capsules)**

(Bioequivalent to and 25% less expensive than originator brand Nexium<sup>®</sup>)

Approved- **GREEN**

### 7.6 **Noqdurna<sup>®</sup> 25 microgram desmopressin oral lyophilisate**

For symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults

Approved- **GREEN**

### 7.7 **Insulin Degludec in patients with Type II diabetes and children**

Approved- **AMBER**. It was agreed that all insulins should be made **AMBER**.

**7.8 Amoxil®- potential cost savings**

Approved- **GREEN**

**7.9 Sompar request for change in traffic light status of SSRIs in under 18 year olds if suitable guidance is provided**

SPF would support the AMBER status of SSRI's in under 18 year olds as set out by Sompar Psychiatrist. Await LMC comments before final agreement.

**Action Robert Munro**

**8 D&TC DECISIONS**

**8.1 Somerset Partnership D&TC- Last meeting 6/12/16**

SD gave update on last meeting shared care guidelines are being reviewed

**8.2 YDH D&TC – last meeting 19/7/16; October meeting cancelled**

Not tabled

**8.3 TST D&TC – last meeting 11/11/16**

CB gave update on last meeting. Trust will be making pethidine non-formulary

**8.4 Taunton & Somerset Antimicrobial Prescribing Group (TSAPG) - next meeting 9/11/16.**

No matters arising

**8.5 RUH Bath DTC: September and November minutes**

No matters arising

**8.6 BNSSG D&TC: no minutes received**

No matters arising

**8.7 BNSSG JFG:September- 16 minutes attached**

No matters arising

**8.8 LPC report**

Not tabled

## Part 2 – Items for information or noting

9 **NICE Guidance** Summary of published guidance noted

9.1 **NICE/NHS England:  
Consultation on changes to technology appraisals and highly specialised technologies**

The consultation was noted and the potential impact on implementation timetable.

9.2 **NICE Patient Access Schemes**

YDH and TST have given assurance that they use all available NICE patient access schemes.

### NICE Technology Appraisals

9.3 **[TA288] Dapagliflozin in combination therapy for treating type 2 diabetes - Update**

Noted and approved

9.4 **[TA417] Nivolumab for previously treated advanced renal cell carcinoma- for noting**

Noted specialist commissioning not funded by CCG. TLS status- **RED**. TLS to be updated

**Action Steve Moore**

9.5 **[TA418] Dapagliflozin in triple therapy for treating type 2 diabetes**

Noted and approved. Check formulary has been updated.

**Action Steve Moore**

9.6 **[TA419] Apremilast for treating moderate to severe plaque psoriasis – previously approved by SPF in response to positive NICE FAD**

Noted and approved. Update TLS with NICE tag- **RED** drug

**Action Steve Moore**

9.7 **[TA420] Ticagrelor for preventing atherothrombotic events after myocardial infarction**

Noted and approved- Ticagrelor will be **AMBER** for this indication and will have an impact on primary care budget. TLS to be updated

**Action Steve Moore**

9.8 **[TA421] Everolimus with exemestane for treating advanced breast cancer after endocrine therapy**

Noted specialist commissioning not funded by CCG. TLS status- **RED**. TLS to be updated.

**Action Steve Moore**

- 9.9 [TA422] Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - for noting**
- Noted specialist commissioning not funded by CCG. TLS status- **RED** TLS to be updated
- Action Steve Moore**
- 9.10 [TA423] Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens- For noting**
- Noted specialist commissioning not funded by CCG. TLS status- **RED** TLS to be updated
- Action Steve Moore**
- 9.11 [TA424] Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer -for noting**
- Noted specialist commissioning not funded by CCG. TLS status- **RED** TLS to be updated
- Action Steve Moore**
- 9.12 [TA425] Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia - for noting**
- Noted specialist commissioning not funded by CCG. TLS status- **RED** TLS to be updated
- Action Steve Moore**
- 9.13 [TA426] Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia - for noting**
- Noted specialist commissioning not funded by CCG. TLS status- **RED** TLS to be updated
- Action Steve Moore**
- 9.14 [TA427] Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib - for noting**
- Noted specialist commissioning not funded by CCG. TLS status- **RED** TLS to be updated
- Action Steve Moore**
- 9.15 [TA428] Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy - for noting**
- Noted specialist commissioning not funded by CCG. TLS status- **RED** TLS to be updated
- Action Steve Moore**

- 10 NICE Clinical Guidance**
- 10.1 [NG59] Low back pain and sciatica in over 16s: assessment and management**  
MM team to review with reference to specific medicines issues as well as interventions for low back pain. (policies to be updated in line with guidance)  
**Action SG & CH**
- 10.2 [NG18] Diabetes (type 1 and type 2) in children and young people: diagnosis and management**  
Amendment November 2016 noted, recommendations 1.2.115 and 1.3.52 were amended to add information on when eye screening should begin and referral for eye screening should happen. Trust were asked to review internally.
- 10.3 [CG127] Hypertension in adults: diagnosis and management**  
Amendment November 2016 noted
- 10.4 [CG95] Chest pain of recent onset: assessment and diagnosis**  
Amendment November 2016 noted
- 10.5 [CG60] Hypothermia: prevention and management in adults having surgery**  
Amendment December 2016 noted
- 10.6 [NG60] HIV testing: increasing uptake among people who may have undiagnosed HIV (Joint NICE and Public Health England guideline)**  
Noted
- 11 NHS ENGLAND SPECIALIST COMMISSIONING**
- 11.1 NHS England statement on evolocumab for the treatment of homozygous familial hypercholesterolaemia**  
This statement was noted. Trusts to clarify how they diagnose homozygous FH.  
**Action JS CB**
- 11.2 Changes to NHSE Drugs list**  
Changes were noted
- 11.3 List of supportive drugs used in chemotherapy**  
This statement was noted. There is lack of clarity that NHSE will pay trusts for all drugs on the list. Trusts to clarify the position.
- 12 PBR excluded drug monitoring**
- 12.1 T & S Trust Data- Month**  
Current position was reviewed. Areas of overspend was discussed and noted.



## **12.2 YDH Trust data- Month**

Current position was reviewed. Areas of overspend was discussed and noted.

## **12.3 17/18 Trust budget negotiations- update**

Contracts signed for YDH awaiting confirmation of high cost drugs budget. SG noted that there is likely to be some form of risk pool arrangement, but there is debate over which drugs it will cover.

## **13 HORIZON SCANNING**

### **13.1 NICE forward planner - for noting**

Noted

## **14 DRUG SAFETY**

### **14.1 MHRA Drug Safety Update November 2016 - eNewsletter**

Noted

### **14.2 MHRA Drug Safety Update December 2016 - eNewsletter**

Noted

### **14.3 Apremilast letter to Healthcare Professionals**

Noted- CCG newsletter to remind practices of the safety need to ensure RED drugs are appropriately recorded on patient records

**Action Steve Moore**

### **14.4 Lenalidomide (Revlimid®▼): New important advice regarding viral reactivation**

Noted- CCG newsletter to remind practices of the safety need to ensure RED drugs are appropriately recorded on patient records

**Action Steve Moore**

### **14.5 Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects**

Noted- CCG newsletter to remind practices of the safety need to ensure RED drugs are appropriately recorded on patient records

**Action Steve Moore**

## **NHSE Patient Safety Alerts**

### **14.6 Risk of death and severe harm from error with injectable phenytoin**

Noted. Trusts asked to raise awareness.

### **14.7 Risk of severe harm and death due to withdrawing insulin from pen devices**

Noted

## **15 BNF Changes**

November and December eNewsletter – Noted

**16 ANY OTHER BUSINESS**

**16.1 Dermatology requests for primary care to prescribe 'Red' (hospital only drugs)**

This was discussed awaiting further update on dermatology service changes

JS raised BMJ article on refer to pharmacy this will be shared

**Action JS**

All trusts to update SPF on current status of refer to pharmacy scheme

**Action JS, JB & SD**

**DATE OF NEXT MEETING**

**15<sup>th</sup> March 2017 at Wynford House (Meeting Room 1), Lufton Way, Yeovil,  
Somerset BA22 8HR between 2.30pm and 5pm**

**SCHEDULE OF ACTIONS ARISING FROM THE MEETING HELD ON 18<sup>th</sup> Jan 2017**

<b>NO.</b>	<b>SUBJECT</b>	<b>OUTSTANDING RESPONSIBILITY</b>	<b>ACTION LEAD</b>	<b>Status</b>
1	<b>Declarations of interest (1)</b>	Members were asked to notify the Prescribing Forum secretary of any standing declarations of interest, which could be held on record.	<b>All (on going)</b>	<b>Ongoing</b>
2	<b>RuH Biosimilars Policy</b>	Update at next SPF	<b>SG 15<sup>th</sup> March 2017</b>	<b>On Agenda</b>
3	<b>LMWH Bridging Guidance- YDH</b>	JS to update on progress at next meeting	<b>JS 15<sup>th</sup> March 2017</b>	<b>On Agenda</b>
4	<b>TST self-assessment against NICE QS120</b>	JB to update at next meeting	<b>JB 15<sup>th</sup> March 2017</b>	<b>On Agenda</b>
5	<b>SomPar Medicines Management actions against CQC inspection report</b>	SD to update at next meeting	<b>SD 15<sup>th</sup> March 2017</b>	<b>Complete</b>
6	<b>Trust letters RE: Shared Care arrangements</b>	Trusts to amend letter to set a timescale for rejection, if shared care not agreed.	<b>JS, JB &amp; SD 15<sup>th</sup> March 2017</b>	<b>Complete</b>
7	<b>ADHD and dementia drug shared care protocols</b>	To bring final draft to SPF for approval next meeting	<b>SD 15<sup>th</sup> March 2017</b>	<b>On agenda</b>
8	<b>Respiratory guidelines and Inhaler pathways</b>	To share videos and leaflets	<b>Steve Moore 15<sup>th</sup> March 2017</b>	<b>Complete</b>
9	<b>Symphony lead pharmacist SPF membership</b>	Obtain contacts and add Kate Jones to circulation list and membership	<b>CH &amp; ZT 15<sup>th</sup> March 2017</b>	<b>Complete</b>
10	<b>Traffic light status of SSRIs in under 18 year olds if suitable guidance is provided</b>	Await LMC comments	<b>Robert Munro 15<sup>th</sup> March 2017</b>	<b>On Agenda</b>
11	<b>Low back pain and sciatica in over 16s: assessment and management</b>	Local intervention policies to be reviewed and updated. Specific medicines issues to be identified.	<b>CH &amp; SG 15<sup>th</sup> March 2017</b>	<b>Complete</b>

NO.	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	Status
12	NHS England statement on evolocumab for the treatment of homozygous familial hypercholesterolaemia	Trusts to clarify how they diagnose homozygous FH	CB & JS 15th March 2017	On agenda
13	BMJ article 'Refer to pharmacy'	JS to share	JS 15th March 2017	Completed
14	Current status of refer to pharmacy scheme	Update SPF on current status	JS, JB & SD 15th March 2017	On agenda
15	Formulary/ Traffic Light Changes	<ul style="list-style-type: none"> <li>• Braltus® Inhaler- Approved <b>GREEN</b></li> <li>• Sialanar® oral solution- Approved <b>GREEN</b> Colonis brand of glycopyrronium liquid to be removed</li> <li>• Acidex® Advance - Approved <b>GREEN</b></li> <li>• Pipexus® tablets - Approved <b>GREEN</b></li> <li>• Ventra® Capsules- Approved <b>GREEN</b></li> <li>• Noqdurna® oral lyophilisate - Approved <b>GREEN</b></li> <li>• Insulin Degludec in patients with Type II diabetes and children - Approved <b>AMBER.</b></li> <li>• All insulins to be made <b>AMBER.</b></li> <li>• Amoxil®- Approved <b>GREEN</b></li> </ul>	Steve Moore 15th March 2017	Complete

NO.	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	Status
15	Formulary/ Traffic Light Changes	<ul style="list-style-type: none"> <li>• <b>Ticagrelor for preventing atherothrombotic events after myocardial infarction - Approved AMBER</b></li> <li>• Revised inhaler pathways update formulary.</li> <li>• <b>Nivolumab for previously treated advanced renal cell carcinoma- specialist commissioning not funded by CCG- RED</b></li> <li>• <b>Dapagliflozin in triple therapy for treating type 2 diabetes- Check on formulary</b></li> <li>• <b>Apremilast for treating moderate to severe plaque psoriasis- CCG funded RED</b></li> <li>• <b>Ticagrelor for preventing atherothrombotic events after myocardial infarction- AMBER</b></li> <li>• <b>Everolimus with exemestane for treating advanced breast cancer after endocrine therapy- specialist commissioning not funded by CCG- RED</b></li> <li>• <b>Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer- specialist commissioning not funded by CCG- RED</b></li> <li>• <b>Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens- specialist commissioning not funded by CCG- RED</b></li> </ul>	Steve Moore 15th March 2017	Complete

NO.	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	Status
15	Formulary/ Traffic Light Changes	<ul style="list-style-type: none"> <li>• <b>Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer-</b> specialist commissioning not funded by CCG- <b>RED</b></li> <li>• <b>Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia-</b> specialist commissioning not funded by CCG- <b>RED</b></li> <li>• <b>Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia-</b> specialist commissioning not funded by CCG- <b>RED</b></li> <li>• <b>Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib-</b> specialist commissioning not funded by CCG- <b>RED</b></li> <li>• <b>Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy-</b> specialist commissioning not funded by CCG- <b>RED</b></li> </ul>	Steve Moore 15th March 2017	Complete
16	Newsletter Articles	<ul style="list-style-type: none"> <li>• To remind practices of the safety need to ensure <b>RED</b> drugs are appropriately recorded on patient records.</li> </ul>	Steve Moore 15th March 2017	In progress